Last updated: 2026-09-28 20:38:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Tvardi Therapeutics, Inc. (TVRD) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.33, with a market capitalisation of $16.94M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.93 to $43.65. This page covers its latest market performance, valuation, price trends and company information.
$16.94M | |
$1.27 | |
$43.65 | |
$0.93 | |
$1.27 | |
339.80K | |
2.35M | |
-- | |
$43.65 | |
$0.93 | |
-- | |
-- |
Tvardi Therapeutics, Inc. (TVRD) is trading at $1.33 in after-hours trading as of 2026-09-28 20:35:00, up 4.72% ($0.06) from the regular-session close of $1.27.
After-hours trading shows how investors are pricing TVRD after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Tvardi Therapeutics, Inc. (TVRD) moved from $1.62 to $1.33, representing a decline of 18.15% ($0.29).
The stock traded between $0.93 and $1.74 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 330.04 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0.9%
TVRD is currently trading at $1.33, placing it 0.9% of the way from its 52-week low of $0.93 to its 52-week high of $43.65. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 12 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Tvardi Therapeutics, Inc. (TVRD) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.